Cl-NQTrp|cas:185351-23-9|西域试剂

Cl-NQTrp,98.06%

产品编号：Bellancom-138643| CAS NO：185351-23-9| 分子式：C₂₁H₁₅ClN₂O₄| 分子量：394.81

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-138643		￥4000.00	杭州北京（现货）
Bellancom-138643		￥6400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cl-NQTrp

产品介绍

Cl-NQTrp 显著破坏 tau 衍生的 PHF6 (VQIVYK) 肽和全长 tau 蛋白的预制纤维聚集物。

生物活性

Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein.

体外研究

Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils.
Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau.
Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav^c155 -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control.
Dosage:	0.75 mg/mL.
Administration:	Dripped every other day.
Result:	Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav^c155 -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control.
Dosage:	0.75 mg/mL.
Administration:	Dripped every other day.
Result:	Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau).

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (633.22 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5329 mL	12.6643 mL	25.3286 mL
5 mM	0.5066 mL	2.5329 mL	5.0657 mL
10 mM	0.2533 mL	1.2664 mL	2.5329 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.27 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.27 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.27 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.27 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明